Cystitis Pipeline Review 2021

Cystitis is the medical term dealing with inflammation of the bladder. Mainly, the inflammation is caused by bacterial infection and it is termed as urinary tract infection (UTI). The infection of bladder is painful which leads to serious health problem and further affects kidneys. Frequently, cystitis may arise due to reaction to certain drugs, radiation therapy or potential irritants, such as spermicidal jellies, feminine hygiene spray, or long-term use of a catheter.

Antibiotics is the common treatment for bacterial cystitis. As per the data published by American Urological Association, it is projected that, 150 million UTIs occur yearly, which accounts for around US$ 6 billion in healthcare expenditures. Antibiotics such as trimethoprim-sulfamethoxazole, nitrofurantoin, cephalosporin, amoxicillin, ciprofloxacin, and levofloxacin are used for the treatment of bacterial cystitis. In addition, pentosane, histamine blockers, and immunosuppressant, such as mycophenolate and cyclosporine can be used to treat the pain associated with interstitial cystitis.

Approximately 60% of pipeline drugs for Cystitis are in phase 2 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent Cystitis.

Report Description

The report on Cystitis- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for Cystitis. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

• Assessment of pipeline products based on various stages of devolvement.
• Provides an overview of the global therapeutic landscape of Cystitis (Infectious Disease).
• Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
• The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
• Latest news, articles, press-release, and related conferences

• Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
• Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
• Build strategic initiatives by understanding the focus areas of leading companies
• Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline